Genomic damage in endstage renal disease-contribution of uremic toxins

Toxins

Volumn 2, Issue 10, 2010, Pages 2340-2358

  Schupp, Nicole ^a   Heidland, August ^a   Stopper, Helga ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Dialysis; Genotoxicity; Uremic toxins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANGIOTENSIN II; BENFOTIAMINE; C REACTIVE PROTEIN; CREATININE; CYANOCOBALAMIN; DIMETHYLNITROSAMINE; FOLIC ACID; HOMOCYSTEINE; HYDROQUINONE; INDICAN; INTERLEUKIN 6; LEPTIN; METHYLGLYOXAL; N EPSILON (CARBOXYMETHYL)LYSINE; N METHYL 2 PYRIDONE 5 CARBOXAMIDE; PHOSPHORUS; REACTIVE OXYGEN METABOLITE; THIAMINE; THIOCYANATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; UREMIC TOXIN;

ANTIOXIDANT ACTIVITY; COMBINATION CHEMOTHERAPY; DIALYSIS MEMBRANE; DNA DAMAGE; GENOTOXICITY; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; MONOTHERAPY; MORTALITY; OXIDATIVE STRESS; PERITONEAL DIALYSIS; QUALITY OF LIFE; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; RISK REDUCTION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

DIETARY SUPPLEMENTS; DNA DAMAGE; HUMANS; KIDNEY FAILURE, CHRONIC; MUTAGENS; RENAL REPLACEMENT THERAPY; TOXINS, BIOLOGICAL; VITAMINS;

EID: 79952098353     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins2102340     Document Type: Review

References (144)

1. Coresh, J.; Selvin, E.; Stevens, L.A.; Manzi, J.; Kusek, J.W.; Eggers, P.; Van Lente, F.; Levey, A.S. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298, 2038-2047.
2. Maisonneuve, P.; Agodoa, L.; Gellert, R.; Stewart, J.H.; Buccianti, G.; Lowenfels, A.B.; Wolfe, R.A.; Jones, E.; Disney, A.P.; Briggs, D.; McCredie, M.; Boyle, P. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999, 354, 93-99.
3. Stewart, J.H.; Buccianti, G.; Agodoa, L.; Gellert, R.; McCredie, M.R.; Lowenfels, A.B.; Disney, A.P.; Wolfe, R.A.; Boyle, P.; Maisonneuve, P. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J. Am. Soc. Nephrol. 2003, 14, 197-207.
4. Teschner, M.; Garte, C.; Rückle-Lanz, H.; Mader, U.; Stopper, H.; Klassen, A.; Heidland, A. Incidence and spectrum of malignant disease among dialysis patients in North Bavaria. Dtsch. Med. Wochenschr. 2002, 127, 2497-2502.
5. Kan, E.; Undeger, U.; Bali, M.; Basaran, N. Assessment of DNA strand breakage by the alkaline COMET assay in dialysis patients and the role of Vitamin E supplementation. Mutat. Res. 2002, 520, 151-159.
6. Horoz, M.; Bolukbas, F.F.; Bolukbas, C.; Aslan, M.; Koylu, A.O.; Gunaydin, N.; Selek, S.; Kocyigit, A. The association of circulating leptin level with peripheral DNA damage in hemodialysis subjects. Clin. Biochem. 2006, 39, 918-922.
7. Stopper, H.; Boullay, F.; Heidland, A.; Vienken, J.; Bahner, U. Comet-assay analysis identifies genomic damage in lymphocytes of uremic patients. Am. J. Kidney Dis. 2001, 38, 296-301.
8. Vamvakas, S.; Bahner, U.; Becker, P.; Steinle, A.; Gotz, R.; Heidland, A. Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immunosuppression after renal transplantation. Transplant. Proc. 1996, 28, 3468-3473.
9. Herbert, K.E.; Mistry, Y.; Hastings, R.; Poolman, T.; Niklason, L.; Williams, B. Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways. Circ. Res. 2008, 102, 201-208.
10. Li, H.; Mitchell, J.R.; Hasty, P. DNA double-strand breaks: a potential causative factor for mammalian aging? Mech. Ageing Dev. 2008, 129, 416-424.
11. Mercer, J.; Mahmoudi, M.; Bennett, M. DNA damage, p53, apoptosis and vascular disease. Mutat. Res. 2007, 621, 75-86.
12. Loft, S.; Poulsen, H.E. Cancer risk and oxidative DNA damage in man. J. Mol. Med. 1996, 74, 297-312.
13. Buemi, M.; Floccari, F.; Costa, C.; Caccamo, C.; Belghity, N.; Campo, S.; Pernice, F.; Bonvissuto, G.; Coppolino, G.; Barilla, A.; Criseo, M.; Crasci, E.; Nostro, L.; Arena, A. Dialysis-related genotoxicity: sister chromatid exchanges and DNA lesions in T and B lymphocytes of uremic patients. Genomic damage in patients on hemodiafiltration. Blood Purif. 2006, 24, 569-574.
14. Stopper, H.; Meysen, T.; Bockenforde, A.; Bahner, U.; Heidland, A.; Vamvakas, S. Increased genomic damage in lymphocytes of patients before and after long-term maintenance hemodialysis therapy. Am. J. Kidney Dis. 1999, 34, 433-437.
15. Roth, J.M.; Restani, R.G.; Goncalves, T.T.; Sphor, S.L.; Ness, A.B.; Martino-Roth, M.G.; Garcias, G.L. Genotoxicity evaluation in chronic renal patients undergoing hemodialysis and peritoneal dialysis, using the micronucleus test. Genet. Mol. Res. 2008, 7, 433-443.
16. Lim, P.S.; Ma, Y.S.; Cheng, Y.M.; Chai, H.; Lee, C.F.; Chen, T.L.; Wei, Y.H. Mitochondrial DNA mutations and oxidative damage in skeletal muscle of patients with chronic uremia. J. Biomed. Sci. 2002, 9, 549-560.
17. Lim, P.S.; Cheng, Y.M.; Wei, Y.H. Large-scale mitochondrial DNA deletions in skeletal muscle of patients with end-stage renal disease. Free Radic. Biol. Med. 2000, 29, 454-463.
18. Liu, C.S.; Ko, L.Y.; Lim, P.S.; Kao, S.H.; Wei, Y.H. Biomarkers of DNA damage in patients with end-stage renal disease: mitochondrial DNA mutation in hair follicles. Nephrol. Dial. Transplant. 2001, 16, 561-565.
19. Domenici, F.A.; Vannucchi, M.T.; Jordao, A.A., Jr.; Meirelles, M.S.; Vannucchi, H. DNA oxidative damage in patients with dialysis treatment. Ren. Fail. 2005, 27, 689-694.
20. Nakabeppu, Y.; Sakumi, K.; Sakamoto, K.; Tsuchimoto, D.; Tsuzuki, T.; Nakatsu, Y. Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids. Biol. Chem. 2006, 387, 373-379.
21. Vanholder, R.; De Smet, R.; Glorieux, G.; Argiles, A.; Baurmeister, U.; Brunet, P.; Clark, W.; Cohen, G.; De Deyn, P.P.; Deppisch, R.; et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003, 63, 1934-1943.
22. Vanholder, R.; Van Laecke, S.; Glorieux, G. What is new in uremic toxicity? Pediatr. Nephrol. 2008, 23, 1211-1221.
23. McGregor, D. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties. Crit. Rev. Toxicol. 2007, 37, 887-914.
24. Schupp, N.; Schinzel, R.; Heidland, A.; Stopper, H. Genotoxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors. Ann. N. Y. Acad. Sci. 2005, 1043, 685-695.
25. Wheelhouse, N.M.; Chan, Y.S.; Gillies, S.E.; Caldwell, H.; Ross, J.A.; Harrison, D.J.; Prost, S. TNF-alpha induced DNA damage in primary murine hepatocytes. Int. J. Mol. Med. 2003, 12, 889-894.
26. Schmid, U.; Stopper, H.; Heidland, A.; Schupp, N. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab. Res. Rev. 2008, 24, 371-377.
27. Vanholder, R.C.; Glorieux, G.; De Smet, R.; De Deyn, P.P. Low water-soluble uremic toxins. Adv. Ren. Replace. Ther. 2003, 10, 257-269.
28. Bakir, A.; Williams, R.H.; Shaykh, M.; Dunea, G.; Dubin, A. Biochemistry of the uremic syndrome. Adv. Clin. Chem. 1992, 29, 61-120.
29. Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160, 1-40.
30. Halliwell, B. Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radic. Res. 1996, 25, 57-74.
31. Kao, M.P.; Ang, D.S.; Pall, A.; Struthers, A.D. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J. Hum. Hypertens. 2010, 24, 1-8.
32. Oberg, B.P.; McMenamin, E.; Lucas, F.L.; McMonagle, E.; Morrow, J.; Ikizler, T.A.; Himmelfarb, J. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004, 65, 1009-1016.
33. Dounousi, E.; Papavasiliou, E.; Makedou, A.; Ioannou, K.; Katopodis, K.P.; Tselepis, A.; Siamopoulos, K.C.; Tsakiris, D. Oxidative stress is progressively enhanced with advancing stages of CKD. Am. J. Kidney Dis. 2006, 48, 752-760.
34. Terawaki, H.; Yoshimura, K.; Hasegawa, T.; Matsuyama, Y.; Negawa, T.; Yamada, K.; Matsushima, M.; Nakayama, M.; Hosoya, T.; Era, S. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int. 2004, 66, 1988-1993.
35. Jackson, P.; Loughrey, C.M.; Lightbody, J.H.; McNamee, P.T.; Young, I.S. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin. Chem. 1995, 41, 1135-1138.
36. Spittle, M.A.; Hoenich, N.A.; Handelman, G.J.; Adhikarla, R.; Homel, P.; Levin, N.W. Oxidative stress and inflammation in hemodialysis patients. Am. J. Kidney Dis. 2001, 38, 1408-1413.
37. Richard, M.J.; Arnaud, J.; Jurkovitz, C.; Hachache, T.; Meftahi, H.; Laporte, F.; Foret, M.; Favier, A.; Cordonnier, D. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991, 57, 10-15.
38. Mimic-Oka, J.; Simic, T.; Ekmescic, V.; Dragicevic, P. Erythrocyte glutathione peroxidase and superoxide dismutase activities in different stages of chronic renal failure. Clin. Nephrol. 1995, 44, 44-48.
39. Vaziri, N.D.; Dicus, M.; Ho, N.D.; Boroujerdi-Rad, L.; Sindhu, R.K. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 2003, 63, 179-185.
40. Locatelli, F.; Canaud, B.; Eckardt, K.U.; Stenvinkel, P.; Wanner, C.; Zoccali, C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol. Dial. Transplant. 2003, 18, 1272-1280.
41. Cachofeiro, V.; Goicochea, M.; de Vinuesa, S.G.; Oubina, P.; Lahera, V.; Luno, J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int. Suppl. 2008, 74, S4-S9.
42. Blowey, D.L.; Alon, U.S. Dialysis principles for primary health-care providers. Clin. Pediatr. (Phila) 2005, 44, 19-27.
43. Divino Filho, J.C. Preservation of renal function: HDF versus PD. The paramount role of peritoneal dialysis. Blood Purif. 2004, 22 (Suppl. 2), 34-35.
44. Roob, J.M. Comparison of clinical outcomes in peritoneal dialysis and hemodialysis. Wien. Klin. Wochenschr. 2005, 117 (Suppl. 6), 60-68.
45. Fenton, S.S.; Schaubel, D.E.; Desmeules, M.; Morrison, H.I.; Mao, Y.; Copleston, P.; Jeffery, J.R.; Kjellstrand, C.M. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am. J. Kidney Dis. 1997, 30, 334-342.
46. Oreopoulos, D.G.; Ossareh, S.; Thodis, E. Peritoneal dialysis: past, present, and future. Iran. J. Kidney Dis. 2008, 2, 171-182.
47. Ting, G.O.; Kjellstrand, C.; Freitas, T.; Carrie, B.J.; Zarghamee, S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am. J. Kidney Dis. 2003, 42, 1020-1035.
48. Williams, A.W.; Chebrolu, S.B.; Ing, T.S.; Ting, G.; Blagg, C.R.; Twardowski, Z.J.; Woredekal, Y.; Delano, B.; Gandhi, V.C.; Kjellstrand, C.M. Early clinical, quality-of-life, and biochemical changes of ''daily hemodialysis'' (6 dialyses per week). Am. J. Kidney Dis. 2004, 43, 90-102.
49. Floridi, A.; Antolini, F.; Galli, F.; Fagugli, R.M.; Floridi, E.; Buoncristiani, U. Daily haemodialysis improves indices of protein glycation. Nephrol. Dial. Transplant. 2002, 17, 871-878.
50. Rocco, M.V. More frequent hemodialysis: back to the future? Adv. Chronic Kidney Dis. 2007, 14, e1-e9.
51. Lornoy, W.; Becaus, I.; Billiouw, J.M.; Sierens, L.; Van Malderen, P.; D'Haenens, P. On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations. Nephrol. Dial. Transplant. 2000, 15 (Suppl. 1), 49-54.
52. Lin, C.L.; Yang, C.W.; Chiang, C.C.; Chang, C.T.; Huang, C.C. Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif. 2001, 19, 301-307.
53. Rabindranath, K.S.; Strippoli, G.F.; Daly, C.; Roderick, P.J.; Wallace, S.; MacLeod, A.M. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. Cochrane Database Syst. Rev. 2006, CD006258. DOI: 10.1002/14651858.CD006258.
54. Canaud, B.; Bragg-Gresham, J.L.; Marshall, M.R.; Desmeules, S.; Gillespie, B.W.; Depner, T.; Klassen, P.; Port, F.K. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int. 2006, 69, 2087-2093.
55. Thomas, G.; Jaber, B.L. Convective therapies for removal of middle molecular weight uremic toxins in end-stage renal disease: a review of the evidence. Semin. Dial. 2009, 22, 610-614.
56. Penne, E.L.; van der Weerd, N.C.; Blankestijn, P.J.; van den Dorpel, M.A.; Grooteman, M.P.; Nube, M.J.; Ter Wee, P.M.; Levesque, R.; Bots, M.L. Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. Clin. J. Am. Soc. Nephrol. 2010, 5, 80-86.
57. Canaud, B.; Morena, M.; Leray-Moragues, H.; Chalabi, L.; Cristol, J.P. Overview of clinical studies in hemodiafiltration: what do we need now? Hemodial. Int. 2006, 10 (Suppl. 1), S5-S12.
58. Locatelli, F.; Manzoni, C.; Cavalli, A.; Di Filippo, S. Can convective therapies improve dialysis outcomes? Curr. Opin. Nephrol. Hypertens. 2009, 18, 476-480.
59. Filiopoulos, V.; Hadjiyannakos, D.; Metaxaki, P.; Sideris, V.; Takouli, L.; Anogiati, A.; Vlassopoulos, D. Inflammation and oxidative stress in patients on hemodiafiltration. Am. J. Nephrol. 2008, 28, 949-957.
60. Gonzalez-Diez, B.; Cavia, M.; Torres, G.; Abaigar, P.; Muniz, P. Effect of a hemodiafiltration session with on-line regeneration of the ultrafiltrate on oxidative stress. Comparative study with conventional hemodialysis with polysulfone. Blood Purif. 2008, 26, 505-510.
61. Vaslaki, L.; Major, L.; Berta, K.; Karatson, A.; Misz, M.; Pethoe, F.; Ladanyi, E.; Fodor, B.; Stein, G.; Pischetsrieder, M.; Zima, T.; Wojke, R.; Gauly, A.; Passlick-Deetjen, J. On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif. 2006, 24, 163-173.
62. Calo, L.A.; Naso, A.; Carraro, G.; Wratten, M.L.; Pagnin, E.; Bertipaglia, L.; Rebeschini, M.; Davis, P.A.; Piccoli, A.; Cascone, C. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol. Dial. Transplant. 2007, 22, 1413-1419.
63. Calo, L.A.; Naso, A.; Davis, P.A. Hemodiafiltration and oxidative stress in dialysis patients. Blood Purif. 2009, 28, 59-60.
64. Kobras, K.; Schupp, N.; Nehrlich, K.; Adelhardt, M.; Bahner, U.; Vienken, J.; Heidland, A.; Sebekova, K.; Stopper, H. Relation between different treatment modalities and genomic damage of end-stage renal failure patients. Kidney Blood Press. Res. 2006, 29, 10-17.
65. Kopple, J.D. National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am. J. Kidney Dis. 2001, 37, S66-S70.
66. Charra, B.; Calemard, E.; Cuche, M.; Laurent, G. Control of hypertension and prolonged survival on maintenance hemodialysis. Nephron 1983, 33, 96-99.
67. Charra, B.; Chazot, C.; Jean, G.; Hurot, J.M.; Vanel, T.; Terrat, J.C.; VoVan, C. Long 3 × 8 hr dialysis: a three-decade summary. J. Nephrol. 2003, 16 (Suppl. 7), S64-S69.
68. Kliger, A.S. More intensive hemodialysis. Clin. J. Am. Soc. Nephrol. 2009, 4 (Suppl. 1), S121-S124.
69. McFarlane, P.A. More of the same: improving outcomes through intensive hemodialysis. Semin. Dial. 2009, 22, 598-602.
70. Ok, E.; Duman, S.; Asci, G.; Yilmaz, M.; Sertoz, O.O.; Toz, H.; Adam, S.M.; Basci, A.; Ozkahya, M. Eight-hour nocturnal in-center hemodialysis provides survival benefit over four-hour conventional hemodialysis. J. Am. Soc. Nephrol. 2008, 19, 71A.
71. Kjellstrand, C.M.; Buoncristiani, U.; Ting, G.; Traeger, J.; Piccoli, G.B.; Sibai-Galland, R.; Young, B.A.; Blagg, C.R. Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years. Nephrol. Dial. Transplant. 2008, 23, 3283-3289.
72. Punal, J.; Lema, L.V.; Sanhez-Guisande, D.; Ruano-Ravina, A. Clinical effectiveness and quality of life of conventional haemodialysis versus short daily haemodialysis: a systematic review. Nephrol. Dial. Transplant. 2008, 23, 2634-2646.
73. Koshikawa, S.; Akizawa, T.; Saito, A.; Kurokawa, K. Clinical effect of short daily in-center hemodialysis. Nephron Clin. Pract. 2003, 95, c23-c30.
74. Traeger, J.; Galland, R.; Delawari, E.; Arkouche, W.; Hadden, R. Six years' experience with short daily hemodialysis: do the early improvements persist in the mid and long term? Hemodial. Int. 2004, 8, 151-158.
75. Buoncristiani, U.; Fagugli, R.M.; Pinciaroli, M.R.; Kulurianu, H.; Ceravolo, G.; Bova, C. Reversal of left-ventricular hypertrophy in uremic patients by treatment with daily hemodialysis (DHD). Contrib. Nephrol. 1996, 119, 152-156.
76. Galland, R.; Traeger, J.; Arkouche, W.; Delawari, E.; Fouque, D. Short daily hemodialysis and nutritional status. Am. J. Kidney Dis. 2001, 37, S95-S98.
77. Reynolds, J.T.; Homel, P.; Cantey, L.; Evans, E.; Harding, P.; Gotch, F.; Wuerth, D.; Finkelstein, S.; Levin, N.; Kliger, A.; Simon, D.B.; Finkelstein, F.O. A one-year trial of in-center daily hemodialysis with an emphasis on quality of life. Blood Purif. 2004, 22, 320-328.
78. Buoncristiani, U. Fifteen years of clinical experience with daily haemodialysis. Nephrol. Dial. Transplant. 1998, 13 (Suppl. 6), 148-151.
79. Fagugli, R.M.; Buoncristiani, U.; Ciao, G. Anemia and blood pressure correction obtained by daily hemodialysis induce a reduction of left ventricular hypertrophy in dialysed patients. Int. J. Artif. Organs 1998, 21, 429-431.
80. Nesrallah, G.E.; Suri, R.S.; Zoller, R.; Garg, A.X.; Moist, L.M.; Lindsay, R.M. The International Quotidian Dialysis Registry: annual report 2006. Hemodial. Int. 2006, 10, 219-224.
81. Ayus, J.C.; Mizani, M.R.; Achinger, S.G.; Thadhani, R.; Go, A.S.; Lee, S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J. Am. Soc. Nephrol. 2005, 16, 2778-2788.
82. Galland, R.; Traeger, J. Short daily hemodialysis and nutritional status in patients with chronic renal failure. Semin. Dial. 2004, 17, 104-108.
83. Friedman, A.N.; Bostom, A.G.; Levey, A.S.; Rosenberg, I.H.; Selhub, J.; Pierratos, A. Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. J. Am. Soc. Nephrol. 2002, 13, 265-268.
84. Fagugli, R.M.; Vanholder, R.; De Smet, R.; Selvi, A.; Antolini, F.; Lameire, N.; Floridi, A.; Buoncristiani, U. Advanced glycation end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis. Int. J. Artif. Organs 2001, 24, 256-262.
85. Yuen, D.; Richardson, R.M.; Fenton, S.S.; McGrath-Chong, M.E.; Chan, C.T. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. ASAIO J. 2005, 51, 236-241.
86. Hamlett, L.; Haragsim, L. Quotidian hemodialysis and inflammation associated with chronic kidney disease. Adv. Chronic Kidney Dis. 2007, 14, e35-e42.
87. Fragedaki, E.; Nebel, M.; Schupp, N.; Sebekova, K.; Volkel, W.; Klassen, A.; Pischetsrieder, M.; Frischmann, M.; Niwa, T.; Vienken, J.; Heidland, A.; Stopper, H. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis. Nephrol. Dial. Transplant. 2005, 20, 1936-1943.
88. Makoff, R. Vitamin replacement therapy in renal failure patients. Miner. Electrolyte Metab. 1999, 25, 349-351.
89. Waxman, S.; Corcino, J.J.; Herbert, V. Drugs, toxins and dietary amino acids affecting vitamin B12 or folic acid absorption or utilization. Am. J. Med. 1970, 48, 599-608.
90. Muller, C.; Eisenbrand, G.; Gradinger, M.; Rath, T.; Albert, F.W.; Vienken, J.; Singh, R.; Farmer, P.B.; Stockis, J.P.; Janzowski, C. Effects of hemodialysis, dialyser type and iron infusion on oxidative stress in uremic patients. Free Radic. Res. 2004, 38, 1093-1100.
91. Tarng, D.C.; Huang, T.P.; Liu, T.Y.; Chen, H.W.; Sung, Y.J.; Wei, Y.H. Effect of vitamin E-bonded membrane on the 8-hydroxy 2'-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int. 2000, 58, 790-799.
92. Cruz, D.N.; de Cal, M.; Ronco, C. Oxidative stress and a nemia in chronic hemodialysis: the promise of bioreactive membranes. Contrib. Nephrol. 2008, 161, 89-98.
93. Takouli, L.; Hadjiyannakos, D.; Metaxaki, P.; Sideris, V.; Filiopoulos, V.; Anogiati, A.; Vlassopoulos, D. Vitamin E-coated cellulose acetate dialysis membrane: long-term effect on inflammation and oxidative stress. Ren. Fail. 2010, 32, 287-293.
94. Matsumura, M.; Sasaki, H.; Sekizuka, K.; Sano, H.; Ogawa, K.; Shimizu, C.; Yoshida, H.; Kobayashi, S.; Koremoto, M.; Aritomi, M.; Ueki, K. Improved management of intradialytic hypotension (IDH) using vitamin E-bonded polysulfone membrane dialyzer. Int. J. Artif. Organs 2010, 33, 147-153.
95. Schleicher, E.D.; Bierhaus, A.; Haring, H.U.; Nawroth, P.P.; Lehmann, R. Chemistry and pathobiology of advanced glycation end products. In Advanced Glycation End Products in Nephrology; D'Angelo, A., Favaro, S., Gambaro, G., Eds.; Kager: Basel, Switzerland, 2001; Contrib. Nephrol. Vol. 131, pp. 1-9.
96. Busch, M.; Franke, S.; Ruster, C.; Wolf, G. Advanced glycation end-products and the kidney. Eur. J. Clin. Invest. 2010, 40, 742-755.
97. Brownlee, M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 1995, 46, 223-234.
98. Miyata, T.; Wada, Y.; Cai, Z.; Iida, Y.; Horie, K.; Yasuda, Y.; Maeda, K.; Kurokawa, K.; van Ypersele de Strihou, C. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int. 1997, 51, 1170-1181.
99. Miyata, T.; van Ypersele de Strihou, C.; Kurokawa, K.; Baynes, J.W. Alterations in nonenzymatic biochemistry in uremia: origin and significance of ''carbonyl stress'' in long-term uremic complications. Kidney Int. 1999, 55, 389-399.
100. Agalou, S.; Ahmed, N.; Thornalley, P.J.; Dawnay, A. Advanced glycation end product free adducts are cleared by dialysis. Ann. N. Y. Acad. Sci. 2005, 1043, 734-739.
101. Kalousova, M.; Zima, T.; Tesar, V.; Stipek, S.; Sulkova, S. Advanced glycation end products in clinical nephrology. Kidney Blood Press. Res. 2004, 27, 18-28.
102. Miyata, T. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure. Nippon Jinzo Gakkai Shi 1996, 38, 191-197.
103. Miyata, T.; Kawai, R.; Taketomi, S.; Sprague, S.M. Possible involvement of advanced glycation end-products in bone resorption. Nephrol. Dial. Transplant. 1996, 11 (Suppl. 5), 54-57.
104. Miyata, T.; Kurokawa, K.; van Ypersele de Strihou, C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int. Suppl. 2000, 76, S120-S125.
105. Wendt, T.; Tanji, N.; Guo, J.; Hudson, B.I.; Bierhaus, A.; Ramasamy, R.; Arnold, B.; Nawroth, P.P.; Yan, S.F.; D'Agati, V.; Schmidt, A.M. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14, 1383-1395.
106. Wautier, M.P.; Chappey, O.; Corda, S.; Stern, D.M.; Schmidt, A.M.; Wautier, J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 2001, 280, E685-E694.
107. Schmidt, A.M.; Yan, S.D.; Yan, S.F.; Stern, D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 2001, 108, 949-955.
108. Hammes, H.P.; Du, X.; Edelstein, D.; Taguchi, T.; Matsumura, T.; Ju, Q.; Lin, J.; Bierhaus, A.; Nawroth, P.; Hannak, D.; Neumaier, M.; Bergfeld, R.; Giardino, I.; Brownlee, M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 2003, 9, 294-299.
109. Balakumar, P.; Rohilla, A.; Krishan, P.; Solairaj, P.; Thangathirupathi, A. The multifaceted therapeutic potential of benfotiamine. Pharmacol. Res. 2010, 61, 482-488.
110. Peyroux, J.; Sternberg, M. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes. Pathol. Biol. 2006, 54, 405-419.
111. Head, K.A. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern. Med. Rev. 2006, 11, 294-329.
112. Frank, T.; Bitsch, R.; Maiwald, J.; Stein, G. High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfontiamine. Eur. J. Clin. Pharmacol. 2000, 56, 251-257.
113. Lange, K.; Lonergan, E.T.; Semar, M.; Sterzel, R.B. Transketolase inhibition as a mechanism in uremic neuropathy. Trans. Assoc. Am. Physicians 1971, 84, 172-181.
114. Ueda, K.; Takada, D.; Mii, A.; Tsuzuku, Y.; Saito, S.K.; Kaneko, T.; Utsumi, K.; Iino, Y.; Katayama, Y. Severe thiamine deficiency resulted in Wernicke's encephalopathy in a chronic dialysis patient. Clin. Exp. Nephrol. 2006, 10, 290-293.
115. Hung, S.C.; Hung, S.H.; Tarng, D.C.; Yang, W.C.; Chen, T.W.; Huang, T.P. Thiamine deficiency and unexplained encephalopathy in hemodialysis and peritoneal dialysis patients. Am. J. Kidney Dis. 2001, 38, 941-947.
116. Blumberg, A.; Hanck, A.; Sander, G. Vitamin nutrition in patients on continuous ambulatory peritoneal dialysis (CAPD). Clin. Nephrol. 1983, 20, 244-250.
117. Eckert, M.; Schejbal, P. Therapy of neuropathies with a vitamin B combination. Symptomatic treatment of painful diseases of the peripheral nervous system with a combination preparation of thiamine, pyridoxine and cyanocobalamin. Fortschr. Med. 1992, 110, 544-548.
118. Frank, T.; Bitsch, R.; Maiwald, J.; Stein, G. Alteration of thiamine pharmacokinetics by end-stage renal disease (ESRD). Int. J. Clin. Pharmacol. Ther. 1999, 37, 449-455.
119. Schupp, N.; Dette, E.M.; Schmid, U.; Bahner, U.; Winkler, M.; Heidland, A.; Stopper, H. Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 378, 283-291.
120. Schmid, U.; Stopper, H.; Heidland, A.; Schupp, N. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab. Res. Rev. 2008, 24, 371-377.
121. Wu, S.; Ren, J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci. Lett. 2006, 394, 158-162.
122. Ferechide, D.; Radulescu, D. Hyperhomocysteinemia in renal diseases. J. Med. Life 2009, 2, 53-59.
123. Miyaki, K. Genetic polymorphisms in homocysteine metabolism and response to folate intake: a comprehensive strategy to elucidate useful genetic information. J. Epidemiol. 2010, 20, 266-270.
124. Yi, P.; Melnyk, S.; Pogribna, M.; Pogribny, I.P.; Hine, R.J.; James, S.J. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J. Biol. Chem. 2000, 275, 29318-29323.
125. Dodge, J.E.; Okano, M.; Dick, F.; Tsujimoto, N.; Chen, T.; Wang, S.; Ueda, Y.; Dyson, N.; Li, E. Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J. Biol. Chem. 2005, 280, 17986-17991.
126. Fenech, M. Micronucleus frequency in human lymphocytes is related to plasma vitamin B12 and homocysteine. Mutat. Res. 1999, 428, 299-304.
127. Vianna, A.C.; Mocelin, A.J.; Matsuo, T.; Morais-Filho, D.; Largura, A.; Delfino, V.A.; Soares, A.E.; Matni, A.M. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial. Int. 2007, 11, 210-216.
128. Chiu, Y.W.; Chang, J.M.; Hwang, S.J.; Tsai, J.C.; Chen, H.C. Pharmacological dose of vitamin B12 is as effective as low-dose folinic acid in correcting hyperhomocysteinemia of hemodialysis patients. Ren. Fail. 2009, 31, 278-283.
129. Cianciolo, G.; La Manna, G.; Coli, L.; Donati, G.; D'Addio, F.; Persici, E.; Comai, G.; Wratten, M.; Dormi, A.; Mantovani, V.; Grossi, G.; Stefoni, S. 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients. Am. J. Nephrol. 2008, 28, 941-948.
130. Ossareh, S.; Shayan-Moghaddam, H.; Salimi, A.; Asgari, M.; Farrokhi, F. Different doses of oral folic acid for homocysteine-lowering therapy in patients on hemodialysis: a randomized controlled trial. Iran. J. Kidney Dis. 2009, 3, 227-233.
131. Heinz, J.; Kropf, S.; Domrose, U.; Westphal, S.; Borucki, K.; Luley, C.; Neumann, K.H.; Dierkes, J. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010, 121, 1432-1438.
132. Jamison, R.L.; Hartigan, P.; Kaufman, J.S.; Goldfarb, D.S.; Warren, S.R.; Guarino, P.D.; Gaziano, J.M. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298, 1163-1170.
133. Brady, C.B.; Gaziano, J.M.; Cxypoliski, R.A.; Guarino, P.D.; Kaufman, J.S.; Warren, S.R.; Hartigan, P.; Goldfarb, D.S.; Jamison, R.L. Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study. Am. J. Kidney Dis. 2009, 54, 440-449.
134. Stopper, H.; Treutlein, A.T.; Bahner, U.; Schupp, N.; Schmid, U.; Brink, A.; Perna, A.; Heidland, A. Reduction of the genomic damage level in haemodialysis patients by folic acid and vitamin B12 supplementation. Nephrol. Dial. Transplant. 2008, 23, 3272-3279.
135. Schupp, N.; Schmid, U.; Rutkowski, P.; Lakner, U.; Kanase, N.; Heidland, A.; Stopper, H. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am. J. Physiol. 2007, 292, F1427-F1434.
136. Schmid, U.; Stopper, H.; Schweda, F.; Queisser, N.; Schupp, N. Angiotensin II induces DNA damage in the kidney. Cancer Res. 2008, 68, 9239-9246.
137. Luo, L.; Jiang, L.; Geng, C.; Cao, J.; Zhong, L. Hydroquinone-induced genotoxicity and oxidative DNA damage in HepG2 cells. Chem. Biol. Interact. 2008, 173, 1-8.
138. Kim, J.; Kim, N.H.; Sohn, E.; Kim, C.S.; Kim, J.S. Methylglyoxal induces cellular damage by increasing argpyrimidine accumulation and oxidative DNA damage in human lens epithelial cells. Biochem. Biophys. Res. Commun. 2010, 391, 346-351.
139. Rutkowski, P. Are so-called uremic toxins always toxic? J. Ren. Nutr. 2008, 18, 7-11.
140. Erkekoglu, P.; Baydar, T. Evaluation of the protective effect of ascorbic acid on nitrite- and nitrosamine-induced cytotoxicity and genotoxicity in human hepatoma line. Toxicol. Mech. Methods 2010, 20, 45-52.
141. Rothfuss, A.; O'Donovan, M.; De Boeck, M.; Brault, D.; Czich, A.; Custer, L.; Hamada, S.; Plappert-Helbig, U.; Hayashi, M.; Howe, J.; et al. Collaborative study on fifteen compounds in the rat-liver Comet assay integrated into 2- and 4-week repeat-dose studies. Mutat. Res. 2010, 702, 40-69.
142. Majer, B.J.; Hofer, E.; Cavin, C.; Lhoste, E.; Uhl, M.; Glatt, H.R.; Meinl, W.; Knasmuller, S. Coffee diterpenes prevent the genotoxic effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N-nitrosodimethylamine in a human derived liver cell line (HepG2). Food Chem. Toxicol. 2005, 43, 433-441.
143. Milligan, J.R.; Aguilera, J.A.; Paglinawan, R.A.; Ward, J.F. Mechanism of DNA damage by thiocyanate radicals. Int. J. Radiat. Biol. 2000, 76, 1305-1314.
144. Babbar, N.; Casero, R.A., Jr. Tumor necrosis factor-alpha increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis. Cancer Res. 2006, 66, 11125-11130.